Les Laboratoires Servier
http://www.servier.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Les Laboratoires Servier
Boehringer, Bayer Kinase Inhibitors Offer Oral Option In HER2-Mutated Lung Cancer
Boehringer presented Phase Ib results for zongertinib and Bayer presented Phase I/II results for BAY 2927088 in NSCLC with HER2 mutations – a rare cancer with ADC Enhertu as a major competitor – at the WCLC meeting.
Chinese Cell And Gene Therapies Enjoy Limelight Amid Summer Fundraising Lull
CorrectSequence led the pack of Chinese cell and gene therapy developers seeking new funding with a roughly $14m series A-plus round. In other modalities, antibody-focused developers Mabgeek and Novamab closed series Bs.
Deal Watch: Lilly Turns To Oblique For Antibody Discovery
Plus deals involving Lilly/Oblique, Rafael Holdings/Cyclo, ADCendo/Multitude, Ocuvex/Visiox and more.
Finance Watch: OS Therapies Raises $6.4m In Year’s 14th Biopharma IPO In The US
Public Company Edition: OS Therapies launched this year’s smallest initial public offering, to fund its lead program in osteosarcoma. Also, Australian firm Telix, after opting out of a US IPO, grossed A$650m ($425.5m) from investors at home. Day One raised $175m in a private placement.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
-
Biotechnology
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
-
- Biogaran SAS
- Egis Pharmaceuticals plc
- WeHealth
- Servier BioInnovation
- Symphogen A/S
- Servier Pharmaceuticals, LLC.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice